Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Pharmaceuticals in India Stories

2012-08-23 02:25:43

REDWOOD CITY, Calif., Aug. 23, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the following investor conferences: 2012 Southern California Investor ConferenceDate: Thursday, August 30, 2012 at 1:30 p.m. PDT (4:30 p.m....

2012-08-23 02:25:36

NEW YORK, Aug. 23, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the Company strengthened the management team with the hiring of Jack V. Talley as President and Chief Executive Officer and Enza Guagenti as Chief Financial Officer. Mr. Talley is a pharmaceutical industry veteran with more than thirty years of experience in marketing, drug development and regulatory...

2012-08-22 10:25:14

NEW YORK and PITTSBURGH, Aug. 22, 2012 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Mylan Inc. (Nasdaq: MYL) today announced that they have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. The collaboration is designed to build upon each company's highly complementary strengths and quality assets. Under the terms of the agreement, Pfizer's responsibilities primarily consist of the...

2012-08-22 06:24:20

PARSIPPANY, N.J. and MUMBAI, India, Aug. 22, 2012 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received tentative US FDA approval for marketing a generic version of 20mg, 40mg, 60mg & 80mg capsules containing Ziprasidone hydrochloride, which is used in the treatment of bipolar disorders and schizophrenia. Ziprasidone capsule is the generic name for the brand Geodon(®), marketed in the US by Pfizer. Wockhardt will launch the product on Sept 02, 2012. (Logo:...

2012-08-22 02:21:53

NEW YORK, Aug. 22, 2012 /PRNewswire/ -- Pharmspective, LLC, a market research firm providing syndicated research and knowledge management applications to the pharmaceutical industry, today announced the release of its research report: State Exchanges: Opportunities and Threats for Key Health Insurers/Implications for Pharmaceutical Manufacturers: http://www.pharmspective.com/healthcare-reform-state-exchanges/.This assessment is a first-of-its kind look into the likely market dynamics...

2012-08-21 10:24:19

POINT RICHMOND, Calif., Aug. 21, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the U.S. Food and Drug Administration has listed U.S. Patent No. 8,242,131 (the '131 patent) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or "Orange Book." This patent, which was issued by the United States Patent and Trademark Office (USPTO) on August 14, 2012, includes claims directed to methods of treating middle-of-the-night insomnia with low...

2012-08-21 10:23:47

PARSIPPANY, N.J. and MUMBAI, India, Aug. 21, 2012 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used in treating hypertension. Felodipine is the generic name for the brand Plendil(®), marketed in the United States by Astra Zeneca. Wockhardt is launching the product immediately. (Logo:...

2012-08-21 02:27:57

In the news release, Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen, issued 21-Aug-2012 by Inspiration Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first subheadline should read "Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up to a potential value of $215 million" rather than "Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up to...

2012-08-21 02:26:21

DALLAS, Texas, August 21, 2012 /PRNewswire/ -- RnRMarketResearch.com adds a new market research report "Global Markets for Asthma & COPD Drugs" to its store. This report projects a five-year CAGR of 4.4% for the Global Asthma and Chronic Obstructive Pulmonary Disease Drugs market. The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012...

2012-08-20 02:31:50

PARSIPPANY, N.J., Aug. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched an authorized generic version of Xopenex(® )(levalbuterol HCl) Inhalation Solution as part of an agreement with Sunovion Pharmaceuticals, Inc. Watson began shipping the product today. Xopenex(® )Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible...